Since his unforgettable introduction to the rap scene, Tekashi 6ix9ine has been a highly controversial figure who has landed himself in more legal issues!
From snitching on his associates, resulting in lengthy prison sentences for them, to admitting to a child sexual offense, the Bushwick rapper has made the news again as he faces a lawsuit for exposing the alleged heroin use by a tattoo artist named Takashi Matsuba.
“I lost a number of friends, but by far the most important one is my dear wife,” Matsuba stated in the lawsuit. “We divorced last year, because she no longer trusted me after Hernandez’s false statements about me were broadcast on Hulu and Showtime.”
Both 6ix9ine and “Showtime” are named as direct defendants in the complaint.
According to TMZ, Matsuba’s name was inspired by 6ix9ine, as he explained the origin of his name in documentaries on “Hulu” and “Showtime.”
However, when discussing Matsuba, 6ix9ine stated that the tattoo artist had been a heroin addict in the past. As Matsuba notes, this assertion has caused a great deal of personal strife.
Matsuba goes on to say that his tattooing company has largely collapsed due to “the false suggestion that I may be a drug user,” as he points out the consequences of 6ix9ine’s assertion.
This is not the first time 6ix9ine has been served with a lawsuit or other legal action. Earlier this year, he was hit with a lawsuit for failing to pay an outstanding debt on his American Express card.
6ix9ine is now being sued by American Express for a credit card debt of $120,000. After a while of trying to get repayment from the rapper. pic.twitter.com/JHOxHhbgzV— No Jumper (@nojumper) April 11, 2023
Last April, the Brooklyn rapper faced a $2 million lawsuit alleging he skipped on a concert deal. Last September, he was sued by Fashion Nova for $2.25 million for failing to fulfill his social media contract with the mega fast-fashion brand.
Nonetheless, he has yet to comment on the suit according to Hot New Hip-Hop. Check back for more updates, as this story continues to develop.